EICHORPublic-registry site landscape for NCT05219578, “RTX-224 Monotherapy in Patients With Solid Tumors”, a Non Small Cell Lung Cancer study sponsored by Rubius Therapeutics. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT05219578 (registry record) |
| Study title | RTX-224 Monotherapy in Patients With Solid Tumors |
| Official title | A Phase 1/2 Study of RTX-224 for the Treatment of Patients With Advanced Solid Tumors |
| Sponsor | Rubius Therapeutics |
| Condition(s) | Non Small Cell Lung Cancer; Cutaneous Melanoma; Head and Neck Squamous Cell Carcinoma; Urothelial Carcinoma |
| Phase | PHASE1 / PHASE2 |
| Listed sites | 5 |
| Intervention(s) | RTX-224 |
| Site countries | United States |
Patient-friendly overview of this study: eichor.com/study/NCT05219578.
Eichor generates a preliminary site-risk snapshot for NCT05219578 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
